Kurapa kweAlopecia kunoponesa 80% yebvudzi

Vakuru vane hutsinye alopecia areata (AA) akatora OLUMIANT® (baricitinib) akawana zvakakosha scalp, eyelash uye eyebrow bvudzi regrowth uye inoda kusvika 75% yevaya vakapindura OLUMIANT 4-mg vakawana 90% scalp kufukidzwa pamasvondo e52, Eli Lilly neKambani neIncyte vakazivisa nhasi. paAmerican Academy yeDermatology (AAD) Musangano Wepagore. Muna Kukadzi 2022, iyo US Chikafu neDrug Administration (FDA) yakapa ongororo yekutanga yeOLUMIANT mune yakaoma AA semushonga ungangove wekutanga-muchirwere. Lilly anotarisira sarudzo dzekutonga muUS, European Union neJapan muna 2022.

Mukuongorora kwakabatanidzwa kwemavhiki makumi mashanu nemaviri, varwere vekutanga vaive nerevo Severity ye Chishandiso cheAlopecia (SALT) chikamu che85.5 (85.5% kurasikirwa kwebvudzi remusoro, kana 14.5% kufukidzwa kwebvudzi remusoro); yakaoma AA inotsanangurwa seine SALT mamakisi ≥50 (≥50% kurasikirwa kwebvudzi remusoro). Pakutanga, 69.4% uye 57.9% yakanga ine mashizha anokosha uye kurasikirwa kwebvudzi, maererano, sezvinotsanangurwa neCliniki-Reported Outcome (ClinRO) scores ≥2. Avhareji yezera revarwere yaive makore 37.6, uye kurasikirwa kwebvudzi kunotanga makore makumi maviri nemashanu uye zvinoreva makore 25 kubvira chiratidzo chakatanga.

Pakati pevarwere vakatora OLUMIANT 4-mg, vaviri kubva kune vashanu (39.0%, n = 201 / 515) vakawana hukuru hwebvudzi remusoro, rinotsanangurwa semuyero weSALT ≤20, kana 80% kana kupfuura kufukidzwa kwebvudzi remusoro, uye dzinenge nhatu kunze. yevana vevarwere ivavo (74.1%, n = 149/201) vakawanawo chikamu cheSALT ≤10, kana 90% kufukidzwa kwebvudzi, pamasvondo makumi mashanu nemaviri. Kuparadzaniswa, vanopfuura vaviri kubva kune vashanu varwere vane ClinRO yekutanga zvibodzwa ≥52 (tsiye: 2%, n = 44.1/154; eyelash: 349%, n = 45.3/139) vakaona kuzara kuzere kana kumera zvakare kune mashoma mashoma mutsiye uye eyelash. bvudzi.

Pakati pevarwere vakatora OLUMIANT 2-mg, vanopfuura mumwe chete pavashanu (22.6%, n = 77/340) vakawana hukuru hwebvudzi remusoro uye vaviri kubva kune vatatu vevarwere ivavo (67.5%, n = 52/77) vakawana 90 % kana kupfuura kufukidzwa kwebvudzi pamasvondo makumi mashanu nemaviri. Zvakaparadzana, vanopfuura mumwe muvashanu uye mumwe muvarwere vana, zvichiteerana (tsiye: 52%, n = 22.9/55; eyelash: 240%, n = 25.5/51), yakaona kuzara kuzere kana kumera zvakare kune mashoma mashoma mutsiye uye eyelash. bvudzi.

Idzi ongororo dzakabatanidzwa dzemavhiki makumi mashanu nembiri dzinoratidza kuenderera mberi kwekuvandudza mumusoro, tsiye uye kumerazve kwebvudzi kubva mumhedzisiro yemavhiki makumi matatu nematanhatu yakaburitswa nhasi muNew England Journal of Medicine uye yakaunzwa pa52 European Academy yeDermatology uye Venereology (EADV) Congress.

“Kunyangwe vanhu vane alopecia areata vachirasikirwa nebvudzi rese pamuviri wavo kana mhanza nekushaikwa kwetsiye kana tsiye, chirwere che autoimmune ichi chinogona kurwadza. Chirwere ichi chinobata vanhu vemazera ose,” akadaro Brett King, MD, Ph.D., FAAD, akabatana napurofesa wedermatology paYale School of Medicine uye munyori mukuru weongororo idzi. “Muna 2022, OLUMIANT inogona kuve mushonga wekutanga kubvumidzwa kurapa vanhu vakuru vane alopecia areata. Zvinoshamisa kuti vangangoita 40% yevarwere vari paOLUMIANT 4-mg, vese vakatanga neinenge 50% kurasikirwa kwebvudzi remusoro, vaine ruzivo rwakakwana kana rwakazara kana rwakazara vhudzi rakavharika, uye kuvandudzwa kwakafanana kwakaitika pakati pevarwere vane tsiye dzakakosha kana eyelashes. kubatanidzwa."

Mukuongororwa kweOLUMIANT 4-mg uye 2-mg kuchengetedzwa kwenguva refu, zviitiko zvezviitiko zvinowanzotaurwa zvakashata kusvika kumavhiki e52 (yepakati 56 mavhiki kuratidzwa) yaienderana ne36-vhiki, placebo-inodzorwa nguva uye yaisanganisira yepamusoro kufema. kutapukira kweturakiti, kutemwa nemusoro, mburwa, weti turakiti utachiona uye kuwedzera mumhasuru-ane mavanga eropa. Pakanga pasina zviratidzo zvitsva zvekuchengetedza.

“Ruzivo rweOLUMIANT rwenguva refu runoratidza kukura zvakare kwebvudzi remumusoro, retsiye uye retsiye uye tinofara nezvinorehwa nemigumisiro iyi kuvarwere. Yedu alopecia areata yekuchengetedza data inowedzera humwe humbowo kune imwe yakakura uye yakareba seti yedata rekuchengetedza mukirasi yeJAK inhibitor, kusanganisira makore mapfumbamwe uye 19,000 makore evarwere pachirongwa chedu," akadaro Lotus Mallbris, MD, Ph.D., mutevedzeri wemutungamiri. yepasi rose immunology kukura uye zvekurapa nyaya kuLilly. "Tinofara kuti OLUMIANT inogona kunge iri mushonga wekutanga-muchirwere wakabvumidzwa gore rino kune vanhu vakuru vane alopecia areata yakanyanya."